30 closest matches · ranked by relevance
Light Chain Deposition Disease (LCDD or MIDD) · Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) · Monoclonal Immunoglobulin Deposition Disease (MIDD)
Primary: Percentage of Participants Experiencing Progression Free Survival at 12 Months — 84 percentage of patients
Primary Systemic Amyloidosis · Light Chain Deposition Disease
Primary: Complete Hematologic Response — 16 participants
Light-Chain Amyloidosis
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 6; 5; 5; 10 Participants
Amyloidosis
Primary: Maximum Tolerated Dose — 2 participants with DLT
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
Secondary Immunodeficiencies (SID)
Primary: Guideline Adherence (GLAD) — 889; 75; 122 Participants
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Leukemia · Amyloidosis
Primary: Hematologic Response Rate — 2; 4; 8; 9 participants
Primary Systemic Amyloidosis
Primary: Number of Participants With a Confirmed Hematologic Response — 0; 0; 0 participants
AL Amyloidosis
Primary: Number of Participants With Cardiac Response and Non-Response — 26; 30; 40; 33 Participants — p=0.3190
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Membranoproliferative Glomerulonephritis
Primary: Number of Treatment-Emergent Adverse Events — 5 Serious Adverse Events
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Primary Systemic Amyloidosis
Primary: Hematologic Response — 6; 3; 11; 5 Participants
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Amyloidosis · Plasma Cell Myeloma
Primary: Maximum Tolerated (MTD) Dose of Cyclophosphamide With Ixazomib and Dexamethasone (Phase I) — 4; 40 mg weekly
Leukemia · Lymphocytic · Chronic
Primary: Response Rate — 0; 1; 3; 11 Participants
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Primary Immunodeficiency Diseases (PID)
Primary: Validated Acute Serious Bacterial Infection (VASBI) Rate — 0.025 Estimated infections/year — p=<0.0001
Light Chain Deposition Disease · Primary Systemic Amyloidosis
Primary: Proportion of Patients With Hematologic Overall Response (Partial Response [PR]+ Very Good PR [VGPR]+ Amyloid Complete Response [ACR]+ Stringent Complete Response [sCR])…
Multiple Myeloma
Primary: Number of Patients Removed From Study Treatment Due to Toxicities — 31 participants
Chronic Lymphocytic Leukemia (CLL)
Primary: Complete Response — 45 Percentage of Participants
Mantle Cell Lymphoma (MCL)
Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) — 21 participants
FSGS · MCD · Focal Segmental Glomerulosclerosis
Primary: Change in Urine MCP1/Cr Levels — 5.57; 2.89 ng/mg
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
Glomerulonephritis, Membranous
Primary: Percentage of Complete Remission — 4; 3 Participants